HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...
Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the ...
If you're going ... •The ninth annual Braveheart Testimonial Dinner is scheduled for April 19 at the New Englander Banquet Center, 3009 Wilmington Road. Doors open at 5 p.m., and dinner ...
Braveheart Bio, a clinical-stage biotechnology company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, today announced the ...
Braveheart is a new memecoin that launched on Solana. It reached a market capitalization of $2.5 million. Can Braveheart sustain its increase, or will it fade? Braveheart is the latest viral memecoin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results